Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EcoActive in Inactive Crohn's Disease
NCT03808103Phase 2Active, not recruiting
- Sponsor
- Intralytix, Inc.
- Start
- May 2019
- Primary completion
- Jun 2026
- Modality
- Single Strain Products, Multi-strain Products
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of EcoActive in Crohn's disease (2 arms), sponsored by Intralytix, Inc. Primary endpoints: Incidence of adverse events at 6 months, Severity of adverse events at 6 months and 3 more. Started May 2019; status: active, not recruiting.
02
Drugs
EcoActive
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT03808103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03808103.